(Press-News.org) An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.
Patients who showed responses to the drug, nivolumab (anti-PD-1; BMS-936558; MDX-1106; ONO-4538), survived for an average 16.8 months following initiation of treatment. Overall, 62 percent of patients (66 of 107) were alive one year following treatment initiation, and 43 percent (46 of 107) were alive two years later. Average survival among 33 patients (31 percent) whose tumors shrank significantly was two years. The drug is now being tested in three larger, phase III trials in melanoma, which generally compare a new therapy with a standard one currently in use.
Results of the study are published online March 3 in the Journal of Clinical Oncology.
"The results seen here are remarkable for these patients with treatment-resistant, advanced metastatic melanoma, who had limited life expectancies when they joined the trial," says study lead-author Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at Johns Hopkins.
The immune-based therapy aims not to kill cancer cells directly, but to block a pathway that shields tumor cells from immune system components that are potentially able and poised to fight cancer. The pathway includes two proteins called programmed death-1 (PD-1), expressed on the surface of immune cells, and programmed death ligand-1 (PD-L1), expressed on cancer cells. When PD-1 and PD-L1 join together, they form a biochemical shield protecting tumor cells from being destroyed by the immune system. Another protein involved in the pathway, that is expressed by some tumors and by cells in the immune system, is programmed death ligand (PD-L2), which was discovered by Johns Hopkins investigators in 2001.
One hundred seven people with advanced melanoma were given the medication, which is administered intravenously in an outpatient clinic every two weeks. Results suggest that some patients can safely remain on the treatment for up to two years. Participants received doses of 0.1, 0.3, 1, 3, or 10 mg/kg in 12 or fewer eight-week cycles of treatment. Investigators observed responses at all doses, though the highest response rate was in seven of 17 (41 percent) patients receiving 3 mg/kg, the dose now being tested in phase III trials. Participants given that amount survived an average 20.3 months following treatment initiation.
Drug-related adverse events occurred in 84 percent of patients; 22 percent had serious side effects. Among the most common serious side effects were lymphopenia (low levels of infection-fighting white blood cells circulating in the blood); diarrhea; fatigue; and endocrine disorders. Each affected 1-3 percent of participants. There were no drug-related deaths in patients with melanoma receiving nivolumab.
Several companies also are investigating anti-PD1 agents or anti-PD-L1 agents in the treatment of cancers, including melanoma.
Ultimately, investigators envision boosting the effectiveness of the therapy by combining it with other anticancer agents, including cancer vaccines, other immunotherapies, or drugs that block enzymes called kinases, the researchers say.
INFORMATION:
In addition to Topalian, co-authors on the study were William Sharfman, Julie Brahmer, Evan Lipson, Janis Taube and Drew Pardoll from Johns Hopkins; Mario Sznol and Harriet Kluger from Yale's Smilow Cancer Center; David McDermott from Beth Israel Deaconess Medical Center; Donald Lawrence from Massachusetts General Hospital Cancer Center; F. Stephen Hodi from Dana Farber Cancer Institute; Richard Carvajal from Memorial Sloan-Kettering Cancer Center; Michael Atkins from Georgetown-Lombardi Comprehensive Cancer Center; John Powderly from Carolina BioOncology Institute; Philip Leming from The Christ Hospital Cancer Center; Igor Puzanov and Jeffery Sosman from Vanderbilt University Medical Center; David Smith from the University of Michigan Comprehensive Cancer Center; and Jon Wigginton, George Kollia and Ashok Gupta from Bristol-Myers Squibb.
Nivolumab is being developed and manufactured by Bristol-Myers Squibb, which provided funding for the trial along with Ono Pharmaceuticals Co., Ltd. Topalian has served as an uncompensated consultant to Bristol-Myers Squibb and has received research support from the company. Sharfman has served as a consultant to Merck. Brahmer has served as an uncompensated consultant and received research funding from Bristol-Myers Squibb. Pardoll has served as a consultant (uncompensated) to Bristol-Myers Squibb, Jounce Therapeutics, Amplimmune and sanfo-aventis; received research funding from Bristol-Myers Squibb and owns patents related to technology involved in the B7-DC antibody. The terms of these arrangements are being managed by the Johns Hopkins University in accordance with its conflict-of-interest policies.
For more information on the Phase III trial of the drug, see http://www.clinicaltrials.gov and search "nivolumab" or "BMS936558."
Abstract presentation:
#CRA9006 Survival and long-term follow-up of safety and responses in patients with advanced melanoma in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). Presented June 1, 2013 at the American Society of Clinical Oncology.
Related news releases:
http://www.hopkinsmedicine.org/news/media/releases/cancer_therapy_that_boosts_immune_system_ready_for_wider_testing
http://www.hopkinsmedicine.org/news/media/releases/some_melanomas_use_cloaking_protein_to_hide_from_immune_cells
JOHNS HOPKINS MEDICINE
Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $6.7 billion integrated global health enterprise and one of the leading health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins University School of Medicine with the organizations, health professionals and facilities of The Johns Hopkins Hospital and Health System. JHM's mission is to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care. Diverse and inclusive, JHM educates medical students, scientists, health care professionals and the public; conducts biomedical research; and provides patient-centered medicine to prevent, diagnose and treat human illness. JHM operates six academic and community hospitals, four suburban health care and surgery centers, more than 38 primary health care outpatient sites and other businesses that care for national and international patients and activities. The Johns Hopkins Hospital, opened in 1889, was ranked number one in the nation for 21 years by U.S. News & World Report.
Investigational drug may increase survival for some patients with advanced melanoma
2014-03-04
ELSE PRESS RELEASES FROM THIS DATE:
Imprint of chemotherapy linked to inflammation in breast cancer survivors
2014-03-04
Many breast cancer survivors experience fatigue and other debilitating symptoms that persist months to years after their course of treatment has ended.
Now researchers at the Winship Cancer Institute of Emory University have found clues that may explain how these symptoms can linger. Chemotherapy, one of the major treatments for breast cancer, can leave a long-lasting epigenetic imprint in the DNA of breast cancer patients' blood cells. That imprint is associated with biological signs of inflammation up to six months after the completion of treatment. Inflammation in ...
Common cancers evade detection by silencing parts of immune system cells
2014-03-04
Johns Hopkins researchers say they have identified a set of genes that appear to predict which tumors can evade detection by the body's immune system, a step that may enable them to eventually target only the patients most likely to respond best to a new class of treatment.
Immune therapy for ovarian, breast and colorectal cancer — treatments that encourage the immune system to attack cancer cells as the foreign invaders they are — has so far had limited success, primarily because the immune system often can't destroy the cancer cells. In a report published online Feb. ...
'Dimer molecules' aid study of exoplanet pressure, hunt for life
2014-03-04
Astronomers at the University of Washington have developed a new method of gauging the atmospheric pressure of exoplanets, or worlds beyond the solar system, by looking for a certain type of molecule.
And if there is life out in space, scientists may one day use this same technique to detect its biosignature — the telltale chemical signs of its presence — in the atmosphere of an alien world.
Understanding atmospheric pressure is key to knowing if conditions at the surface of a terrestrial, or rocky, exoplanet might allow liquid water, thus giving life a chance.
The ...
Cholesterol study suggests new diagnostic, treatment approach for prostate cancer
2014-03-04
WEST LAFAYETTE, Ind. - Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new diagnostic and treatment methods.
Findings also suggest that a class of drugs previously developed to treat atherosclerosis might be repurposed for treatment of advanced prostate cancer.
The research showed depletion of the compound cholesteryl ester significantly reduced prostate cancer cell proliferation, impaired its ability to invade a laboratory tissue ...
Young children form first impressions from faces
2014-03-04
Just like adults, children as young as 3 tend to judge an individual's character traits, such as trustworthiness and competence, simply by looking at the person's face, new research shows. And they show remarkable consensus in the judgments they make, the findings suggest.
The research, led by psychological scientist Emily Cogsdill of Harvard University, shows that the predisposition to judge others based on physical features starts early in childhood and does not require years of social experience. The study is published in Psychological Science, a journal of the Association ...
Research connects drug war violence in Mexico with desensitization in social media
2014-03-04
Amid times of crisis, citizens often turn to social media as a method to share information, make observations and vent. But as a Georgia Tech professor's research into social media use amid the Mexican drug war shows, posts can reveal growing numbness, or desensitization, during times of protracted violence and stress.
Munmun De Choudhury, formerly of Microsoft Research and now an assistant professor in the School of Interactive Computing at Georgia Tech, led the research. Her team's paper, "'Narco' Emotions: Affect and Desensitization in Social Media during the Mexican ...
Spiral galaxy spills blood and guts
2014-03-04
This new Hubble image shows spiral galaxy ESO 137-001, framed against a bright background as it moves through the heart of galaxy cluster Abell 3627. This cluster is violently ripping the spiral's entrails out into space, leaving bright blue streaks as telltale clues to this cosmic crime.
This new Hubble image shows ESO 137-001, a galaxy located in the southern constellation of Triangulum Australe (The Southern Triangle) -- a delicate and beautiful spiral galaxy, but with a secret.
This image not only captures the galaxy and its backdrop in stunning detail, but also ...
Bright pulses of light could make space veggies more nutritious, says CU-Boulder study
2014-03-04
Exposing leafy vegetables grown during spaceflight to a few bright pulses of light daily could increase the amount of eye-protecting nutrients produced by the plants, according to a new study by researchers at the University of Colorado Boulder.
One of the concerns for astronauts during future extended spaceflights will be the onslaught of eye-damaging radiation they'll be exposed to. But astronauts should be able to mitigate radiation-induced harm to their eyes by eating plants that contain carotenoids, especially zeaxanthin, which is known to promote eye health.
Zeaxanthin ...
New evidence confirms link between IQ and brain cortex
2014-03-04
Rate of change in the thickness of the brain's cortex is an important factor associated with a person's change in IQ, according to a collaborative study by scientists in five countries including researchers at the Montreal Neurological Institute and Hospital – The Neuro, at McGill University and the McGill University Health Centre. The study has potentially wide-ranging implications for the pedagogical world and for judicial cases in which the defendant's IQ score could play a role in determining the severity of the sentence.
The cortex is the thin, outermost layer of ...
Drinking buddies deny copying alcoholic drink orders
2014-03-04
LIVERPOOL, UK – 5 March 2014: People who copy their friend's drinking behaviour will deny that their decision has been influenced, researchers at the University of Liverpool have shown.
A new study, conducted in the University of Liverpool's bar laboratory, a lab designed to imitate a bar, brought together pairs of friends. One of the friends was made aware of the experimental aims and was told to drink alcoholic drinks throughout the session or to stick to soft drinks.
While most people were strongly influenced by peers – they mimicked their friend and drank more ...